Telix Pharmaceuticals Limited has reportedly entered into an agreement with Radius S.r.l for the exclusive commercial distribution of Illuccix, Telix’s prostate cancer imaging product, in Italy.
Under the terms of the contract, Radius will be the exclusive distributor for Illuccix in Italy for three years following the national approval date. The radiotherapy solutions provider had previously partnered with Telix Pharmaceuticals for the distribution of Ga-PSMA-11 for magisterial use in Italy.
It is also worth noting that Radius is the industry leader in the supply of gallium generators across Italy which enables it to provide a secure supply of the gallium required for launching Illuccix. The company is also a service provider and supplier for radiotherapy suites and cyclotrons across Italy which lends it a competitive edge.
Chief Executive Officer of Radius Dr. Mauro Mei was quoted saying that the partnership with Telix Pharmaceuticals will enable the company to provide state-of-the-art PSMA imaging facilities to the 39,000 men diagnosed with prostate cancer in Italy every year following the required regulatory approval.
EMEA President at Telix Pharmaceuticals Richard Valeix mentioned that Italy is an important market considering the high incidence of prostate cancer in the country. He further added that the partnership with Radius, which is already a renowned patient-centric company specializing in nuclear medicine, will enable Telix to achieve its mission of helping cancer patients live longer and better lives.
In 2020, prostate cancer was the most diagnosed type of cancer among Italian men with approximately 39,000 new cases being recorded. It was also a leading cause of cancer-related deaths among men in Italy with 7000 deaths registered during the year.
Source Credits--